# of Displayed Technologies: 2 / 2

Applied Category Filter (Click To Remove): Biologics


Categories

Targeting EGFL7 in AML
TS-037353 — Treatment of blood cancer with anti-EGFL7 antibody.
Despite recent progress in understanding acute myeloid leukemia (AML) biology and the use of intensive treatments, the long-term overall survival is only 30-40% in younger (<60 years) and <10% in older adult AML patients. This highlights the urgent need for novel therapeutic approaches for a…
  • College: College of Medicine (COM)
  • Inventors: Dorrance, Adrienne; Garzon, Ramiro; Shen, Changxian
  • Licensing Officer: Ezzell, Janel

Engineering Calmodulin Proteins to Treat Ryanopathy-Associated Diseases
TS-032588 — Engineered calmodulin-based therapeutics for the treatment of cardiovascular diseases.
While there are three ryanodine receptors responsible for the release of calcium from intracellular stores during excitation-contraction, ryanodine receptor channel 2 (RyR2) has emerged as an important target in the treatment of cardiac failure. When RyR2 channels cease to effectively regulate int…
  • College: College of Medicine (COM)
  • Inventors: Davis, Jonathan
  • Licensing Officer: Davis, Stewart

Loading icon